IVIG naïve (N = 27) | IVIG prior (N = 35) | |
---|---|---|
Age at SCIG initiation, mean (range) | 50 (30–78) | 51 (26–80) |
SCIG dose [g/kg/week] (range) | 0.14 (0.06–0.29) | 0.15 (0.09–0.22) |
Sex | ||
Female | 17 (63%) | 23 (66%) |
Diagnosis | ||
CVID | 13 (48%) | 11 (31%) |
IgGSD | 8 (30%) | 13 (37%) |
Hypogammaglobulinemia NOS | 5 (19%) | 7 (20%) |
SAD | – | 1 (3%) |
X-linked agammaglobulinemia | – | 1 (3%) |
Unspecified humoral immunodeficiency | 1 (4%) | 2 (6%) |
Comorbidities | ||
Bronchiectasis, CRS, or both | 15 (56%) | 16 (46%) |